Patents by Inventor Akio Ojida
Akio Ojida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002343Abstract: The present invention provides a compound for treating or preventing diseases caused by mitochondrial hyperfission. The present invention provides a compound represented by formula (1): wherein R1 and R1? are each independently hydrogen, an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R2 is an optionally substituted lower alkyl, an optionally substituted lower cycloalkyl, and the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, an optionally substituted lower alkyl, and the like; R5 and R6 are each independently an optionally substituted lower alkyl; an optionally substituted lower cycloalkyl, and the like; X is nitrogen or oxygen; Y is carbon, nitrogen or oxygen; and a broken line represents the presence or absence of a bond; or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof.Type: ApplicationFiled: November 29, 2021Publication date: January 4, 2024Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Eiji KAWANISHI, Akio OJIDA, Motohiro NISHIDA, Yuri KATO
-
Publication number: 20220169613Abstract: Compounds represented by formula (I) below and pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.Type: ApplicationFiled: May 26, 2020Publication date: June 2, 2022Inventors: Akio OJIDA, Naoya SHINDO, Akiyuki NISHIMURA, Motohiro NISHIDA
-
Publication number: 20190359560Abstract: An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.Type: ApplicationFiled: March 19, 2019Publication date: November 28, 2019Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shigehiro OHDO, Naoya MATSUNAGA, Akio OJIDA, Naoya SHINDO
-
Publication number: 20180127358Abstract: An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.Type: ApplicationFiled: January 28, 2016Publication date: May 10, 2018Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Shigehiro OHDO, Naoya MATSUNAGA, Akio OJIDA, Naoya SHINDO
-
Patent number: 8093060Abstract: A compound which captures a multisite phosphorylated peptide or protein specifically to a phosphorylation site and a method for detecting the peptide or protein using the compound. Particularly, a compound which specifically detects an excessively phosphorylated tau protein observed in the brain affected by Alzheimer's disease and a method for diagnosing Alzheimer's disease in vitro or in vivo using the compound are provided. By bringing a metal complex compound having two dipicolylamine (Dpa) moieties and a spacer including a chromogenic or luminescent functional or atom group into contact with a multisite phosphorylated peptide or protein, the compound recognizes the distance between phosphate groups and specifically binds to the peptide or protein, and a multisite phosphorylated peptide or protein or kinase activity is optically detected by measuring the change, or a multisite phosphorylated peptide or protein or kinase activity is imaged by an optical imaging method applying the change in luminescence.Type: GrantFiled: February 25, 2009Date of Patent: January 10, 2012Assignee: Canon Kabushiki KaishaInventors: Itaru Hamachi, Fumio Yamauchi, Tetsuya Yano, Kimihiro Yoshimura, Akio Ojida, Takashi Sakamoto, Masaaki Inoue
-
Patent number: 7629472Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.Type: GrantFiled: June 14, 2007Date of Patent: December 8, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Publication number: 20090233373Abstract: There are provided a novel compound which captures a multisite phosphorylated peptide or protein specifically to a phosphorylation site and a method for detecting a multisite phosphorylated peptide or protein using the same. In particular, there are provided a compound which specifically detects an excessively phosphorylated tau protein observed in the brain affected by Alzheimer's disease and a method for diagnosing Alzheimer's disease in vitro or in vivo using the compound.Type: ApplicationFiled: February 25, 2009Publication date: September 17, 2009Applicants: KYOTO UNIVERSITY, CANON KABUSHIKI KAISHAInventors: Itaru Hamachi, Fumio Yamauchi, Tetsuya Yano, Kimihiro Yoshimura, Akio Ojida, Takashi Sakamoto, Masaaki Inoue
-
Publication number: 20090036416Abstract: A novel non-peptide CXCR4 antagonist has a low molecular-weight and uses various aromatic compounds, each containing a dipicolylamine-zinc complex. This CXCR4 antagonist finds use, e.g., as an anti-HIV agent, a metastasis inhibitor for a malignant tumor, and a chronic rheumatoid arthritis treatment and/or prevention agent.Type: ApplicationFiled: December 27, 2006Publication date: February 5, 2009Applicant: Kyoto UniversityInventors: Nobutaka Fujii, Itaru Hamachi, Akio Ojida, Hirokazu Tamamura, Hideki Nakashima
-
Publication number: 20070276143Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2are as defined above with a compound represented by the general formula: wherein R3, R4and R5 are as defined above, and X is a halogen atom.Type: ApplicationFiled: June 14, 2007Publication date: November 29, 2007Inventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Patent number: 7247732Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.Type: GrantFiled: June 12, 2006Date of Patent: July 24, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Publication number: 20060229457Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.Type: ApplicationFiled: June 12, 2006Publication date: October 12, 2006Inventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Patent number: 7084278Abstract: The present invention provides a method for producing an optically active ?-hydroxy ester compound represented by the general formula: wherein R1 represents an optionally substituted hydrocarbon group and the like, R2 represents a nitrogen-containing heterocyclic group different from R1, which is represented by the general formula: wherein the ring may be substituted and the like, R3 represents an optionally substituted hydrocarbon group and the like, R4 and R5 represent, the same or different, a hydrogen atom, a halogen atom and the like, the symbol “*” represents an optically active center, which comprises reacting in the presence of a cinchona alkaloid and the like a compound represented by the general formula: wherein R1 and R2 are as defined above with a compound represented by the general formula: wherein R3, R4 and R5 are as defined above, and X is a halogen atom.Type: GrantFiled: March 5, 2003Date of Patent: August 1, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Toru Yamano, Naohiro Taya, Akio Ojida
-
Patent number: 7084149Abstract: A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and are useful for preventing and treating a mammal suffering from, for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.Type: GrantFiled: May 22, 2003Date of Patent: August 1, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
-
Patent number: 6960586Abstract: The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like. A compound represented by the formula: wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.Type: GrantFiled: November 19, 2001Date of Patent: November 1, 2005Assignee: Takeda Pharmaceutical Company LimitedInventors: Akihiro Tasaka, Nobuyuki Matsunaga, Akio Ojida, Masami Kusaka
-
Publication number: 20040033935Abstract: The present invention provides a compound having a steroid C17,20-lyase-inhibitory activity and useful for the therapy and prophylaxis of tumor such as prostatism, breast cancer and the like, and a method for efficiently separating an optically active compound of this compound from a mixture of optical isomers thereof, a compound of the formula: 1Type: ApplicationFiled: May 16, 2003Publication date: February 19, 2004Inventors: Akihiro Tasaka, Takenori Hitaka, Nobuyuki Matsunaga, Masami Kusaka, Mari Adachi, Isao Oaki, Akio Ojida
-
Publication number: 20040024039Abstract: The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like.Type: ApplicationFiled: May 16, 2003Publication date: February 5, 2004Inventors: Akihiro Tasaka, Nobuyuki Matsunaga, Akio Ojida, Masami Kusaka
-
Publication number: 20030236274Abstract: A composition containing a compound of the formula: 1Type: ApplicationFiled: May 22, 2003Publication date: December 25, 2003Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
-
Patent number: 6649643Abstract: Imidazol-4-ylmethanols and their uses for preventing and treating primary tumors, metastasis and recurrence of tumors, various symptoms accompanying tumors, prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterine myoma, mastopathy and polycystic ovary syndrome are disclosed.Type: GrantFiled: April 12, 2002Date of Patent: November 18, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka
-
Patent number: 6573289Abstract: A composition containing a compound of the formula: wherein A is a nitrogen-containing heterocyclic group which may be substituted, R1 is a hydrogen atom, hydrocarbon group which may be substituted, or monocyclic aromatic heterocyclic group which may be substituted, R2 is a hydrogen atom or a lower alkyl group which may be substituted, R3, R4, R5, R6, R7, R8 and R9 are independently a hydrogen atom, a hydrocarbon group which may be substituted, a hydroxy group which may be substituted, a thiol group which may be substituted, an amino group which may be substituted, an acyl group or a halogen atom, a salt thereof or a prodrug thereof has steroid C17,20-lyase inhibitory activity, and is useful for preventing and treating for example, primary cancer of malignant tumor, its metastasis and recurrence thereof.Type: GrantFiled: October 18, 2000Date of Patent: June 3, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Akihiro Tasaka, Akio Ojida, Tomohiro Kaku, Masami Kusaka, Masuo Yamaoka